Literature DB >> 34157253

How are central foveal and choroidal thickness affected in patients with mild COVID-19 infection?

Müge Fırat1, Sabiha Kobat1.   

Abstract

The aim of this study was to evaluate the effects of  COVID-19 on central foveal and choroidal thicknesses. Thirty-two patients with a positive SARS-CoV-2 PCR test who received outpatient treatment within the previous two months and 32 healthy controls were included in the study. Patients requiring hospitalization due to COVID-19 as well as the patients who received either intensive care support and/or antiplatelet therapy, smokers, or patients with systemic or ocular diseases were excluded from the study. After full ophthalmological examination, central foveal and choroidal thicknesses were evaluated by using optical coherence tomography. Statistical analysis of the study data demonstrated no significant difference between the groups in terms of age or gender (p>0.05). There was also no statistically significant difference between the groups in terms of central foveal thickness, central choroidal thickness, or nasal 500, nasal 1500, temporal 500, or temporal 500-micron distances (p>0.05 for all parameters). Choroidal and retinal thicknesses were not affected in patients with recent mild COVID 19 without comorbidities.

Entities:  

Year:  2021        PMID: 34157253     DOI: 10.17305/bjbms.2021.5840

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  2 in total

1.  Spectral-domain optical coherence tomography assessment of retinal and choroidal changes in patients with coronavirus disease 2019: a case-control study.

Authors:  Mojtaba Abrishami; Ramin Daneshvar; Zahra Emamverdian; Neda Saeedian; Fariba Tohidinezhad; Saeid Eslami; Mohammad-Reza Ansari-Astaneh
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-06-18

2.  Evaluation of choroidal thickness with OCT in COVID-19 patients with high D-dimer levels.

Authors:  Fatih Cem Gül; Esra Suay Timurkaan
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.